A centralized administrative infrastructure is provided in Core E to facilitate and administratively support the organizational structure and management of the Program Project, and to coordinate communications among the principal investigator, project leaders and core directors, and the External Advisory Board members. In serving as "hub" between the project and core investigators, the external advisors, and the Program's Principal Investigator Core E will help the Principal Investigator and all researcher maintain an integrated and efficiently managed Adult Leukemia Research Center Program. These cohesive administrative services will therefore assist the Principal Investigator in his role overseeing the scientific progress and optimizing the Program Project's scientific productivity.

Public Health Relevance

By providing centralized essential administrative support and budgetary oversight this Core assists all projects and cores on this Program Project Grant in achieving their overall goals of broadening the availability of allogeneic hematopoietic cell transplantation (HCT), decreasing the incidence and severity of Graft-versus-Host Disease, and improving the ability of allogeneic HCT to eradicate malignancy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA018029-39
Application #
8733529
Study Section
Special Emphasis Panel (ZCA1-GRB-T)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
39
Fiscal Year
2014
Total Cost
$197,114
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Jagasia, Madan H; Greinix, Hildegard T; Arora, Mukta et al. (2015) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 21:389-401.e1
Walter, R B; Gyurkocza, B; Storer, B E et al. (2015) Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia 29:137-44
Walter, Roland B; Sandmaier, Brenda M; Storer, Barry E et al. (2015) Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. Biol Blood Marrow Transplant 21:373-8
Mielcarek, Marco; Kirkorian, Anna Yasmine; Hackman, Robert C et al. (2014) Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation. Transplantation 98:563-8
Hoffmeister, Paul A; Storer, Barry E; Baker, K Scott et al. (2014) Nephrolithiasis in pediatric hematopoietic cell transplantation with up to 40 years of follow-up. Pediatr Blood Cancer 61:417-23
Stromnes, Ingunn M; Schmitt, Thomas M; Chapuis, Aude G et al. (2014) Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev 257:145-64
Boyle, Nicole M; Podczervinski, Sara; Jordan, Kim et al. (2014) Bacterial foodborne infections after hematopoietic cell transplantation. Biol Blood Marrow Transplant 20:1856-61
Li, Xiang; Deeg, H Joachim (2014) Murine xenogeneic models of myelodysplastic syndrome: an essential role for stroma cells. Exp Hematol 42:4-10
Fisher, C E; Stevens, A M; Leisenring, W et al. (2014) Independent contribution of bronchoalveolar lavage and serum galactomannan in the diagnosis of invasive pulmonary aspergillosis. Transpl Infect Dis 16:505-10
Raj, Kavita; Pagliuca, Antonio; Bradstock, Kenneth et al. (2014) Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 20:890-5

Showing the most recent 10 out of 1666 publications